Journal ArticleDOI
Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis.
Gerald Gartlehner,Richard A. Hansen,Laura C Morgan,Kylie Thaler,Linda J Lux,Megan Van Noord,Ursula Mager,Patricia Thieda,Bradley N. Gaynes,Tania M Wilkins,Michaela Strobelberger,Stacey W Lloyd,Ursula Reichenpfader,Kathleen N. Lohr +13 more
TLDR
Current evidence does not warrant recommending a particular second-generation antidepressant on the basis of differences in efficacy, but differences in onset of action and adverse events may be considered when choosing a medication.Abstract:
BACKGROUND: Second-generation antidepressants dominate the management of major depressive disorder (MDD), but evidence on the comparative benefits and harms of these agents is contradictory.PURPOSE ...read more
Citations
More filters
Journal ArticleDOI
The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses.
TL;DR: The growth of published systematic reviews and meta-analyses is explored and how often they are redundant, misleading, or serving conflicted interests is estimated.
Journal ArticleDOI
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder Section 3. Pharmacological Treatments
Sidney H. Kennedy,Raymond W. Lam,Roger S. McIntyre,S. Valérie Tourjman,Venkat Bhat,Pierre Blier,Mehrul Hasnain,Fabrice Jollant,Anthony J. Levitt,Glenda MacQueen,Shane McInerney,Diane McIntosh,Roumen Milev,Daniel J. Müller,Sagar V. Parikh,Norma L. Pearson,Arun V. Ravindran,Rudolf Uher +17 more
TL;DR: Evidence-based pharmacological treatments are available for first-line treatment of major depressive disorder and for management of inadequate response, however, given the limitations of the evidence base, pharmacological management of MDD still depends on tailoring treatments to the patient.
Journal ArticleDOI
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Gin S Malhi,Darryl Bassett,Philip Boyce,Richard A. Bryant,Paul B. Fitzgerald,Kristina Fritz,Malcolm Hopwood,Bill Lyndon,Roger T. Mulder,Greg Murray,Richard J Porter,Ajeet B. Singh +11 more
TL;DR: The Mood Disorder CPG is the first Clinical Practice Guideline to address both depressive and bipolar disorders and provides up-to-date recommendations and guidance within an evidence-based framework, supplemented by expert clinical consensus.
Journal ArticleDOI
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines
Anthony J. Cleare,Carmine M. Pariante,Allan H. Young,Ian M. Anderson,D M B Christmas,Philip J. Cowen,Chris Dickens,I. N. Ferrier,John R. Geddes,Simon Gilbody,Peter M. Haddad,Cornelius Katona,Glyn Lewis,Andrea Malizia,RH McAllister-Williams,Paul Ramchandani,Jan Scott,David Taylor,Rudolf Uher +18 more
TL;DR: These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse and stopping treatment.
Journal ArticleDOI
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology
David S. Baldwin,David S. Baldwin,Ian M. Anderson,David J. Nutt,Christer Allgulander,Borwin Bandelow,Johan A. den Boer,David M Christmas,Simon J. C. Davies,Naomi A. Fineberg,Nicky Lidbetter,Andrea Malizia,Paul McCrone,Daniel Nabarro,Catherine O'Neill,Jan Scott,Nic J.A. van der Wee,Hans-Ulrich Wittchen +17 more
TL;DR: This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions.
References
More filters
Journal ArticleDOI
Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication
Ronald C. Kessler,Patricia A. Berglund,Olga Demler,Robert Jin,Kathleen R. Merikangas,Ellen E. Walters +5 more
TL;DR: Lifetime prevalence estimates are higher in recent cohorts than in earlier cohorts and have fairly stable intercohort differences across the life course that vary in substantively plausible ways among sociodemographic subgroups.
Journal ArticleDOI
Evaluating non-randomised intervention studies.
Jonathan J Deeks,Jacqueline Dinnes,Roberto D'Amico,Amanda Sowden,C Sakarovitch,Fujian Song,Mark Petticrew,Douglas G. Altman +7 more
TL;DR: The inability of case-mix adjustment methods to compensate for selection bias and the inability to identify non- randomised studies that are free of selection bias indicate that non-randomised studies should only be undertaken when RCTs are infeasible or unethical.
Journal ArticleDOI
Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
TL;DR: A systematic literature search found that among 74 FDA-registered studies, 31%, accounting for 3449 study participants, were not published, and the increase in effect size ranged from 11 to 69% for individual drugs and was 32% overall.
Journal ArticleDOI
Combination of direct and indirect evidence in mixed treatment comparisons
Guobing Lu,A E Ades +1 more
TL;DR: A range of Bayesian hierarchical models using the Markov chain Monte Carlo software WinBUGS are presented that allow for variation in true treatment effects across trials, and models where the between-trials variance is homogeneous across treatment comparisons are considered.
Journal ArticleDOI
Current methods of the US Preventive Services Task Force: a review of the process.
Russell Harris,Mark Helfand,Steven H. Woolf,Kathleen N. Lohr,Cynthia D. Mulrow,Steven M. Teutsch,David Atkins +6 more
TL;DR: The U.S. Preventive Services Task Force (USPSTF/Task Force) represents one of several efforts to take a more evidence-based approach to the development of clinical practice guidelines.